Pieris Pharms

PIRS NASDAQ
4.630
+0.050
+1.09%
盘后: 4.630 0 0.00% 16:25 07/22 EDT
开盘
4.580
昨收
4.580
最高
4.630
最低
4.311
成交量
21.36万
成交均量(3M)
38.91万
52周最高
6.55
52周最低
2.390
换手率
0.43%
市值
2.28亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Pieris Pharms PIRS股票价格,Pieris Pharms股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.
展开 >

最近浏览

名称
价格
涨跌幅